Satisfaction With Phosphodiesterase 5 Inhibitors Treatment In Patients With Cardiovascular Risk


Last updated date


Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center


By email


[email protected]

Call Now

Eligibility Criteria
The disease, disorder, syndrome, illness, or injury that is being studied.
Erectile Dysfunction
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- CV risk factors

- Male above 18

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Non-informed consent


Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center


[email protected]


Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Erectile DysfunctionA Relative Bioavailability Study Between Two Formulations Of Sildenafil Citrate NCT00904748
  1. Braganca Paulista, SP
18 Years+
Erectile DysfunctionA Study to Evaluate Self-esteem and Relationships in Males With Erectile Dysfuntion NCT00648596
  1. Oulu,
  2. Tampere,
  3. Turku,
  4. Clermont Ferrand,
  5. Le Kremlin Bicentre,
  6. Lyon Cedex 03,
  7. MARSEILLE Cedex 20,
  8. Neuilly-sur-seine,
  9. NICE Cedex 01,
  10. Nimes,
  11. Toulouse,
  12. Bari,
  13. Catania,
  14. Gallarate (va),
  15. Modena,
  16. Padova,
  17. Roma,
  18. Siena,
  19. Torino,
  20. Krakow,
  21. Lodz,
  22. Lublin,
  23. Olsztyn,
  24. Szczecin,
  25. Warszawa,
  26. Moscow, Russia
  27. Moscow, Russia
  28. Moscow, Russia
  29. Moscow, Russia
  30. Moscow, Russia
  31. Novosibirsk, Russia
  32. Rostov-on-don, Russia
  33. St. Petersburg, Russia
  34. St. Petersburg, Russia
  35. Barnaul,
  36. Ekaterinburg,
  37. Moscow,
  38. Moscow,
  39. Moscow,
  40. Nizhny Novgorod,
  41. Novosibirsk,
  42. Saint-Petersburg,
  43. Saint-Petersburg,
  44. San Juan, Alicante
  45. Barakaldo, Vizcaya
  46. Barcelona,
  47. Madrid,
  48. Madrid,
  49. Madrid,
  50. Valencia,
  51. Valencia,
  52. Zaragoza,
  53. Karlshamn,
  54. Malmo,
  55. Skovde,
  56. Stockholm,
  57. Varnamo,
  58. Vastervik,
  59. Bodelwyddan, Denbighshire
  60. South Yorkshire, Dn1 2et
  61. Belmont, Durham
  62. Blackpool, Lancashire
  63. Urmston, Manchester
  64. Ashford, Middlesex
  65. Nr Lichfield, Staffordshire
  66. Addlestone, Surrey
  67. Taunton, Ta1 5da
18 Years+
Advanced Information
Descriptive Information
Brief Title Satisfaction With Phosphodiesterase 5 Inhibitors Treatment In Patients With Cardiovascular Risk
Official Title Satisfaction With Treatment In Patients With Erectile Dysfunction And Cardiovascular Risk And/Or Previous Cardiovascular Event.
Brief Summary Evaluate satisfaction in people treated with IPDE5 inhibitors over time
Detailed Description 12 first patients that are eligible
Study Type Observational
Study Design Observational Model: Cohort
Time Perspective: Prospective
Target Follow-Up Duration Not Provided
Biospecimen Not Provided
Sampling Method Non-Probability Sample
Study Population People with cv risk
Condition Erectile Dysfunction
Intervention Not Provided
Study Groups/Cohorts Questionnaire
filling in questionnaires
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Recruitment Information
Recruitment Status Completed
Actual Enrollment
 (submitted: June 7, 2011)
Original Actual Enrollment
 (submitted: April 1, 2009)
Actual Study Completion Date May 2008
Actual Primary Completion Date May 2008   (Final data collection date for primary outcome measure)
Eligibility Criteria

Inclusion Criteria:

  • CV risk factors
  • Male above 18

Exclusion Criteria:

  • Non-informed consent
Sexes Eligible for Study:Male
Ages 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers No
Contacts Contact information is only displayed when the study is recruiting subjects
Listed Location Countries Not Provided
Removed Location Countries  
Administrative Information
NCT Number NCT00874185
Other Study ID Numbers A1481256
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement Not Provided
Responsible Party Pfizer
Study Sponsor Pfizer
Collaborators Not Provided
Study Director:Pfizer Call CenterPfizer
PRS Account Pfizer
Verification Date February 2013